NIT ENTERPRISES, INC.
PALM BEACH GARDENS, FLORIDA

NIT Enterprises, Inc. (DBA Nucleotide Industrial Technologies) (“NIT”) was created to improve public safety and to provide a new measure of protection for commercial, industrial, and personal products; products that enhance the longevity of living and non-living substances based upon unique proprietary nucleotide, (or “NA” for nucleic acid technologies) developed by our award winning scientist and technology team. This new technology is the infusion of nucleotides into a multiplicity of common products enhanced by their presence. The nucleotides were derived by atomic level research that demonstrates their ability to provide screening of ultraviolet (UV) rays at the molecular level. The Company is authorized to issue an aggregate of 105,000,000 shares of capital stock including 100,000,000 shares of common stock. As with all business venture, the development of new and innovative products has significant risks and uncertainties, even with advanced patented, patent-pending and proprietary technologies and methods, such as NIT. Some of these risks are discussed next, and Management believes these risks are some of the most significant concerns. Nevertheless, this list is not exhaustive and other issues need traditional discussion and reviews. There is a risk that NIT’s products could fail to meet regulatory requirements. Despite the advanced techniques and previous significant success of similar products, various complications could cause a selected product to fail certain regulatory requirements. If the selected product failed, additional monies would be needed to test other products. Such other products could also fail regulatory requirements. There is a risk that NIT’s products, even after completing an initial scientific study, could be difficult to sell, or might not be purchased in volumes sufficient to achieve profitability. NIT’s proposed products have not been commercialized, and no prototypes built. Market risks for new industrial and military applications have increased over the past decade. Tight capital markets and reduced R&D budgets have forced companies to pursue lower risk and later stage licensing methods. Companies typically wait until the product has been shown to be marketable before pursuing an acquisition. Moreover, the proposed markets are difficult to penetrate and characterized by long sales cycles. On the upside, new OTC candidates at this stage can reach values far in excess of anticipated or protection results. NIT is a development-stage company and subject to all of the risks such companies face. Its financial statements required to be filed with the SEC will be qualified on a going concern basis. NIT has minimal working capital and is dependent upon raising most of the capital it is presently seeking as well as up to $500,000 it anticipates it will need over the 12 months following the offering. NIT faces technical and market risks. Risks of either kind could cause any investment in the company to be a material, and potentially complete loss. In space, satellites and spacecraft have been experiencing the full radiation from the sun without benefit of the filtering earth’s atmosphere. Scientists have been monitoring this increased radiation due to sun spot cycles and it is a concern for space based personnel and electronics. So, at a time when we are suffering the most damage to the atmosphere, with increased sun activity, and proliferation of man-made radiation devices, life is experiencing a maximum dose of radiation on earth. Most people are acquainted with UV-A and UV-B from sunblock advertisements. The general public has not been educated on the carcinogenic health, cell mutation, and cell death effects of high frequency UV-B, and industrially generated UV-C, which is present in all UV sterilization products. Cancer and cell death can be thousands of times more probable in these high frequency UV ranges. As previously stated, man-made radiation levels, such as X-Rays and Gamma Rays, are higher than ever before. With NA used as a protective shield, the ionizing radiation can be absorbed and converted to infrared photons that are not harmful. This provides NIT with the capability to use the protective effects of NA in hospitals, clinics, dentist and doctor’s offices and industrial facilities; anywhere radiation is used as a tool. NIT can reduce the weight of a medical vest by approximately 80%. NIT is in the process of jointly developing a lightweight production prototype medical vest with a large vest manufacturer. NIT Enterprises, Inc. (DBA Nucleotide Industrial Technologies) (“NIT”) was created to improve public safety and to provide a new measure of protection for commercial, industrial, and personal products; products that enhance the longevity of living and non-living substances based upon unique proprietary nucleotide, (or “NA” for nucleic acid technologies) developed by our award winning scientist and technology team. This new technology is the infusion of nucleotides into a multiplicity of common products enhanced by their presence. The nucleotides were derived by atomic level research that demonstrates their ability to provide screening of ultraviolet (UV) rays at the molecular level. Learn More About Our Company and Our Team This discovery may be considered one of the most profound and valuable discoveries for technological development in the medical and chemical industries. The potential revenues generated by commercialization of NIT’s NA technology can be exploited through manufacturing NA as a raw material and licensing production. We also expect a myriad of other applications, which are also expected to generate significantly more intellectual property.